According to Vaxart's latest financial reports the company's current EPS (TTM) is -$0.76. In 2022 the company made an earnings per share (EPS) of -$0.84 a decrease over its 2021 EPS that were of -$0.58.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -$0.76 | -9.52% |
2022 | -$0.84 | 44.83% |
2021 | -$0.58 | 65.71% |
2020 | -$0.35 | -65.69% |
2019 | -$1.02 | -55.84% |
2018 | -$2.31 | -57.14% |
2017 | -$5.39 | -40.24% |
2016 | -$9.02 | -4.65% |
2015 | -$9.46 | 309.52% |
2014 | -$2.31 | -42.23% |
2013 | -$4.00 | -62.52% |
2012 | -$10.67 | 46.97% |
2011 | -$7.26 | -1200% |
2010 | $0.66 | -102.7% |
2009 | -$24.42 | 2.78% |
2008 | -$23.76 | -146.15% |
2007 | $51.48 | -181.25% |
2006 | -$63.36 | -55.35% |
2005 | -$141.90 | 152.94% |
2004 | -$56.10 | 466.67% |
2003 | -$9.90 | -600% |
2002 | $1.98 | -98.91% |
2001 | $182.16 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | -$0.06000 | -92.11% | Bahamas |
NRC Health
NRC | $1.19 | -256.58% | ๐บ๐ธ USA |